Xconomy: Gossamer Bio Turns Back from Alternative IPO Path News, Back Bay in the Newsjonathan gertlerFebruary 4, 2019Biotech, IPO
Boston Business Journal: A Potential Inflection Point for Biogen Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJuly 20, 2017Biotech, Boston Business Journal, IPO, Jonathan Gertler
Boston Globe: The End of the IPO Drought Jonathan Gertler Posts, NewsBack Bay Life Science AdvisorsJuly 4, 2017Biotech, Boston Globe, IPO, Jonathan Gertler
Back Bay in the Boston Globe: Crispr IPO Doesn't Hit It's Target News, Back Bay in the NewsBack Bay Life Science AdvisorsOctober 24, 2016Gene Editing, IPO, Investment Banking
